grant
Understanding and targeting epigentic regulation of immune evasion in prostate cancer
NIHUS FederalResearch GrantFY2025BindingC-terminalCRG-2CXCL10CXCL10 geneCancer PatientCancer TreatmentCell BodyCell Communication and SignalingCell SignalingCell modelCell-Mediated Lympholytic CellsCellsCellular modelCharacteristicsCheckpoint inhibitorChemotactic CytokinesClinicComplexCytolytic T-CellCytotoxic T CellCytotoxic T-LymphocytesData SetEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryFutureGeneralized GrowthGenesGrowthHDACHDAC ProteinsHistone DeacetylaseHistone H3Homologous Chemotactic CytokinesHumanHuman GenomeIFI10IFNINP10IP-10ImmuneImmune Cell ActivationImmune EvasionImmune checkpoint inhibitorImmunesImmunityImmunomodulationInfiltrationIntercrinesInterferonsIntracellular Communication and SignalingInvadedKnock-outKnockoutL-LysineLymphocytic InfiltrateLysineMOB-1Malignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant neoplasm of prostateMalignant prostatic tumorMediatingMethylationMiceMice MammalsModelingModern ManMolecular InteractionMurineMusMyeloid-derived suppressor cellsN-terminalNH2-terminalPD-1 antibody therapyPD-1 therapyPD1 antibody therapyPD1 based treatmentPathway interactionsPatientsProstate CAProstate CA therapyProstate CancerProstate Cancer therapyProstate malignancyReaderRefractoryResearchRetrotransposonSCYB10SIS cytokinesShapesSignal PathwaySignal TransductionSignal Transduction SystemsSignalingTCGATestingThe Cancer Genome AtlasTissue GrowthTranscriptTranslatingViralaPD-1 therapyaPD-1 treatmentaPD1 therapyaPD1 treatmentanti-PD-1 therapyanti-PD-1 treatmentanti-PD1 therapyanti-PD1 treatmentanti-cancer therapyanti-programmed cell death 1 therapyanti-programmed cell death protein 1 therapyanti-tumor immune responsebiological signal transductioncancer therapycancer-directed therapychemoattractant cytokinechemokineco-repressorcorepressorepigenetic gene silencingepigenetic regulationepigenetic silencingepigeneticallyepigenomicsflow cytophotometrygIP-10gene co-repressorgene corepressorgenetic co-repressorgenetic corepressorgenome scalegenome-widegenomewideglobal gene expressionglobal transcription profilehuman whole genomeimmune activationimmune check point inhibitorimmune evasiveimmune microenvironmentimmune modulationimmune regulationimmune resistanceimmune-resistantimmunogenicimmunogenicityimmunologic reactivity controlimmunomodulatoryimmunoregulationimmunoregulatoryimmunoresistanceimmunosuppressive microenvironmentimmunosuppressive myeloid cellsimmunosuppressive tumor microenvironmentimprovedinnovateinnovationinnovativeinsightkiller T cellloss of functionloss of function mutationmimicrymyeloid suppressor cellsmyeloid-derived suppressive cellsnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovelnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachontogenypathwayprogrammed cell death protein 1 therapyprostate cancer cellprostate cancer modelprostate cancer treatmentprostate tumor cellprostate tumor modelrecruitresistance mechanismresistant mechanismresponsescRNA sequencingscRNA-seqsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingsuppressive myeloid cellstranscriptometumortumor immune microenvironmenttumor-immune system interactions
Description preview
PROJECT SUMMARY/ABSTRACT
Immune checkpoint inhibitor (ICI)-based therapy revolutionized cancer treatment; however, prostate cancer
(PCa) is known to be generally immune-cold and refractory to ICI in non-selective patients. A lack of cytotoxic
T lymphocyte (CTL) infiltration and the enrichment of myeloid-derived suppressor cells (MDSCs) contribute…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click